dyspnea/breast neoplasms

Metastatic breast cancer can have protean manifestations. Here we present a case of a woman with recurrent breast cancer who presented with acute dyspnea and evidence of right heart strain. Diagnoses of myocardial ischemia and of pulmonary embolus were ruled out and the patient ultimately succumbed

Bilateral diaphragmatic paralysis (BDP) is usually caused by anatomic lesions of both phrenic nerves or generalized neurologic diseases. BDP has also been observed during and after infections, associated with mediastinal tumors, or may have an idiopathic etiology. A 57-year-old woman with breast

: Breast cancer is the most common cancer among women and the second leading cause of cancer death in the world. As treatments advance and survival increases among breast cancer survivors, we will continue to see more obstetric patients exposed to anthracycline drugs. Anthracycline toxicity risk is

A 70-year-old woman with lung metastases from a breast cancer presented with worsening cough and dyspnoea. She recently had a pleurodesis for a malignant pleural effusion. Chest CT scans demonstrated various radiological changes leading to diagnostic challenges. Differential diagnoses included

BACKGROUND Cancer patients often have other noncancer medical conditions. Presence of comorbidities negatively affects cancer survival. OBJECTIVE The aim of this study was to investigate comorbidity, risk factors for comorbidity, and how comorbidity was associated with symptoms and quality of life

Chemotherapy is widely used in the management of patients with advanced breast cancer. However, a considerable proportion of patients experience toxic side effects without gaining benefit. This study aimed to elicit oncologists' views of the goals of chemotherapy for patients with advanced breast

Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare, cancer-related, pulmonary complication that causes hypoxia and pulmonary hypertension. We report on a 42-year-old woman who was diagnosed with recurrent breast cancer that was detected due to the presence of PTTM. Eleven months after

OBJECTIVE Because one of the goals of chemotherapy for metastatic breast cancer is to provide symptom palliation, we were interested in identifying the relationship between tumor shrinkage and improvement in disease-related symptoms. METHODS Three hundred patients enrolled onto a randomized trial of